Postl Magdalena, Danisch Melina, Schrott Fridolin, Kofler Paul, Petrov Patrik, Aust Stefanie, Concin Nicole, Polterauer Stephan, Bartl Thomas
Department of Obstetrics and Gynecology, Division of General Gynecology and Gynecologic Oncology, Medical University Vienna, 1090 Vienna, Austria.
Cancers (Basel). 2024 Sep 27;16(19):3295. doi: 10.3390/cancers16193295.
BACKGROUND/OBJECTIVES: The present study evaluates predictive implications of the pretherapeutic Fibrinogen-Albumin-Ratio Index (FARI) in high-grade serous ovarian cancer (HGSOC) patients undergoing primary cytoreductive surgery.
This retrospective study included 161 patients with HGSOC International Federation of Gynecology and Obstetrics (FIGO) stage ≥ IIb, who underwent primary cytoreductive surgery followed by platinum-based chemotherapy. Associations between the FARI and complete tumor resection status were described by receiver operating characteristics, and binary logistic regression models were fitted.
Higher preoperative FARI values correlated with higher ascites volumes (r = 0.371, < 0.001), and higher CA125 levels (r = 0.271, = 0.001). A high FARI cut at its median (≥11.06) was associated with lower rates of complete tumor resection (OR 3.13, 95% CI [1.63-6.05], = 0.001), and retrained its predictive value in a multivariable model independent of ascites volumes, CA125 levels, FIGO stage, and Charlson Comorbidity Index (CCI).
The FARI appears to act as a surrogate for higher intra-abdominal tumor load. After clinical validation, FARI could serve as a readily available serologic biomarker to complement preoperative patient assessment, helping to identify patients who are likely to achieve complete tumor resection during primary cytoreductive surgery.
背景/目的：本研究评估治疗前纤维蛋白原-白蛋白比值指数（FARI）对接受初次肿瘤细胞减灭术的高级别浆液性卵巢癌（HGSOC）患者的预测意义。
这项回顾性研究纳入了161例国际妇产科联盟（FIGO）分期≥IIb期的HGSOC患者，这些患者接受了初次肿瘤细胞减灭术，随后接受铂类化疗。通过受试者工作特征描述FARI与肿瘤完全切除状态之间的关联，并拟合二元逻辑回归模型。
术前FARI值越高，腹水体积越大（r = 0.371，P < 0.001），CA125水平越高（r = 0.271，P = 0.001）。FARI在中位数处的高截断值（≥11.06）与肿瘤完全切除率较低相关（OR 3.13，95%CI[1.63 - 6.05]，P = 0.001），并且在独立于腹水体积、CA125水平、FIGO分期和Charlson合并症指数（CCI）的多变量模型中保留了其预测价值。
FARI似乎可作为腹腔内肿瘤负荷较高的替代指标。经过临床验证后，FARI可作为一种易于获得的血清生物标志物，以补充术前患者评估，有助于识别在初次肿瘤细胞减灭术中可能实现肿瘤完全切除的患者。
